UNIT 1. ASSAY DEVELOPMENT, ADAPTATION, AND IMPLEMENTATION Unit 1 is a responsible for all assay activities, as well as for post-HTS hit characterization, performing: (a) assay development and adaptation for HTS and HCS, (b) initial characterization of hits through confirmatory assays and ECso/ICsq determination, (c) secondary and orthogonal assays and screens, (d) testing of analogs and chemistry-optimized compounds, and (e) preliminary mode-of-action studies on hits and optimized compounds. Unit 1 surpassed the MLSCN goals with the development and adaptation of 36 primary HTS assays consisting of a variety of read-outs, resulting in 39 screening campaigns thus far. The Unit also developed 27 secondary/counter assays to support the MLSCN projects. Additionally, the Unit supported 22 hit optimization/SAR projects using 41 dose-response assays, generated >24,000 IC50 10-point curves in duplicate and performed >20 mode-of-action studies. Unit 1 is organized into two subunits: subunit 1A will develop and implement all HTS assays, while subunit 1B is responsible for developing and optimizing software algorithms for HCS.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HG005033-02
Application #
7938912
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
2
Fiscal Year
2009
Total Cost
$2,557,977
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Lv, Zongyang; Yuan, Lingmin; Atkison, James H et al. (2018) Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun 9:5145
Pinkerton, Anthony B; Sergienko, Eduard; Bravo, Yalda et al. (2018) Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett 28:31-34
Pagano, Nicholas; Teriete, Peter; Mattmann, Margrith E et al. (2017) An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem 25:6248-6265
Oellrich, Anika; Collier, Nigel; Groza, Tudor et al. (2016) The digital revolution in phenotyping. Brief Bioinform 17:819-30
Ma, Chen-Ting; Sergienko, Eduard A (2016) Time-Resolved Fluorescence Assays. Methods Mol Biol 1439:131-42
Roy, Sudeshna; Ĺ ileikyt?, Justina; Neuenswander, Benjamin et al. (2016) N-Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem 11:283-8
Barak, Larry S; Bai, Yushi; Peterson, Sean et al. (2016) ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse. ACS Chem Biol 11:1880-90
Rozanov, Dmitri; Cheltsov, Anton; Sergienko, Eduard et al. (2015) TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. PLoS One 10:e0129566
Lv, Fengping; Li, Zhi-Fang; Hu, Wenhao et al. (2015) Small molecules enhance functional O-mannosylation of Alpha-dystroglycan. Bioorg Med Chem 23:7661-70
Roy, Sudeshna; Ĺ ileikyt?, Justina; Schiavone, Marco et al. (2015) Discovery, Synthesis, and Optimization of Diarylisoxazole-3-carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem 10:1655-71

Showing the most recent 10 out of 69 publications